Danish giant Novo Nordisk, a diabetes market leader, has partnered with San Francisco Bay Area-based Gilead to collaborate on a NASH clinical trial. The two industry sponsors will combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of patients with NASH.
Recently, a Gilead late-stage study of experimental drug selonsertib failed at meeting main goal during a NASH trial. TrialSite News has written about the emerging NASH crisis. Some predict the NASH market to hit $35 billion as populations increasingly develop the disease.